{
    "clinical_study": {
        "@rank": "90859", 
        "arm_group": {
            "arm_group_label": "S-1 plus LV", 
            "arm_group_type": "Experimental", 
            "description": "All patients were orally treated with S-1 in doses of 40 mg (body surface area (BSA)<1.25 m2), 50 mg (1.25\u2264BSA<1.50 m2) and 60 mg (BSA\u22651.50 m2) b.i.d. on days 1-7 in combination with LV given simultaneously at a \ufb01xed dose of 25 mg b.i.d. on days 1-7, followed by a 7 day rest. Treatment courses were repeated every 2 weeks."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the effectiveness and safety of S-1 plus Leucovorin\n      (1 week on and 1 week off) as first-line treatment for patients with metastatic and\n      recurrent gastric cancer."
        }, 
        "brief_title": "Study of S-1 Plus LV for Advanced Gastric Cancer", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Gastric Cancer", 
        "condition_browse": {
            "mesh_term": "Stomach Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "Patients enrolled in this study were orally treated with S-1 in doses of 40 mg (body surface\n      area (BSA)<1.25 m2), 50 mg (1.25\u2264BSA<1.50 m2) and 60 mg (BSA\u22651.50 m2) b.i.d. on days 1-7 in\n      combination with LV given simultaneously at a \ufb01xed dose of 25 mg b.i.d. on days 1-7,\n      followed by a 7 day rest. Treatment courses were repeated every 2 weeks. Treatment was\n      continued until progressive disease (PD), unacceptable toxicity or patient refusal."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  histologically con\ufb01rmed metastatic or recurrent gastric cancer\n\n          -  with at least one measurable lesion by RECIST criteria\n\n          -  an age of \u2265 18\n\n          -  adequate oral intake\n\n          -  no previous radiotherapy, immunotherapy, biotherapy, hormonotherapy and chemotherapy\n             within 5 years (adjuvant chemotherapy without S-1 was allowed if \ufb01nished 6 months\n             before enrollment)\n\n          -  an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\n          -  adequate bone marrow function, hepatic function and renal functions\n\n        Exclusion Criteria:\n\n          -  a history of hypersensitivity to S-1 or LV, usage of drugs interacting with S-1\n\n          -  serious concomitant conditions (severe heart disease, pulmonary \ufb01brosis, intestinal\n             obstruction, enteroplegia, renal failure, liver failure, pre-existing sensory\n             neuropathy \u2265 grade 2, uncontrolled infections, psychogenic disorders, human\n             immunode\ufb01ciency virus infection, severe diarrhea, nausea, or vomiting, severe ascites\n             or pleural effusion, etc.)\n\n          -  extensive bone metastasis, brain metastasis or meningeal metastasis\n\n          -  another synchronous cancer\n\n          -  surgery within 3 weeks before enrollment\n\n          -  participating in other clinical studies\n\n          -  women who were or to be pregnant, nursing infants, and men who were to conceive\n             children"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "39", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "March 12, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02090153", 
            "org_study_id": "SL for AGC"
        }, 
        "intervention": [
            {
                "arm_group_label": "S-1 plus LV", 
                "description": "40~60mg bid\uff0cd1~7 q2W", 
                "intervention_name": "S-1", 
                "intervention_type": "Drug", 
                "other_name": "tegafur/gimeracil/oteracil potassium"
            }, 
            {
                "arm_group_label": "S-1 plus LV", 
                "description": "LV is given simultaneously at a \ufb01xed dose of 25 mg b.i.d. on days 1-7, followed by a 7 day rest.", 
                "intervention_name": "LV", 
                "intervention_type": "Drug", 
                "other_name": "Leucovorin"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Leucovorin", 
                "Levoleucovorin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Advance Gastric Cancer,", 
            "S-1 plus leucovorin,", 
            "ORR,", 
            "OS,", 
            "TTP,", 
            "TTF,", 
            "Adverse events,", 
            "Pharmacokinetics"
        ], 
        "lastchanged_date": "March 14, 2014", 
        "link": [
            {
                "description": "Long-term outcomes and prognostic factors of patients with advanced gastric cancer treated with S-1 plus cisplatin combination chemotherapy as a first-line treatment.", 
                "url": "http://www.ncbi.nlm.nih.gov/pubmed/23999902"
            }, 
            {
                "description": "S-1-Based Chemotherapy versus Capecitabine-Based Chemotherapy as First-Line Treatment for Advanced Gastric Carcinoma: A Meta-Analysis.", 
                "url": "http://www.ncbi.nlm.nih.gov/pubmed/24349363"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Gaungzhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510060"
                }, 
                "name": "Sun Yat-sen University Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of S-1 Plus Leucovorin (1 Week on and 1 Week Off) as First-line Treatment for Patients With Metastatic and Recurrent Gastric Cancer", 
        "overall_official": {
            "affiliation": "SunYat-sen University Cancer Center", 
            "last_name": "Ruihua Xu, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "The primary endpoint is overall response rate,which equals the rate of patients with CR+PR.", 
            "measure": "Overall Response Rate (ORR)", 
            "safety_issue": "No", 
            "time_frame": "1 year"
        }, 
        "reference": {
            "PMID": "19828562", 
            "citation": "Koizumi W, Boku N, Yamaguchi K, Miyata Y, Sawaki A, Kato T, Toh Y, Hyodo I, Nishina T, Furuhata T, Miyashita K, Okada Y. Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer. Ann Oncol. 2010 Apr;21(4):766-71. doi: 10.1093/annonc/mdp371. Epub 2009 Oct 14."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02090153"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Sun Yat-sen University", 
            "investigator_full_name": "Ruihua Xu", 
            "investigator_title": "vice president of SunYat-sen University Cancer Center,head of medical oncology department", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Progression-free survival (PFS) was determined from the date of treatment to progression or death", 
                "measure": "Progression free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "1-1.5 years"
            }, 
            {
                "description": "Overall survival (OS) was calculated from the date of treatment to death from any cause or the last date of follow-up.", 
                "measure": "Overall survival (OS)", 
                "safety_issue": "No", 
                "time_frame": "1-2.5 years"
            }, 
            {
                "description": "Time to treatment failure (TTF) was determined from the date of treatment to progression, death, refusal or interruption due to adverse events.", 
                "measure": "Time to treatment failure (TTF)", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "Disease control rate equals the rate of patients with CR+PR+SD.", 
                "measure": "Disease control rate", 
                "safety_issue": "No", 
                "time_frame": "1 year"
            }, 
            {
                "description": "All treatment-related adverse events (AEs) were categorized according to the National Cancer Institute's Common Terminology Criteria for Adverse Events.", 
                "measure": "Adverse Events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "2 year"
            }
        ], 
        "source": "Sun Yat-sen University", 
        "sponsors": {
            "collaborator": {
                "agency": "Taiho Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Sun Yat-sen University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2011", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}